Four days after the initial injection of 3.6 mg of goserelin acetate, severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up.
flare-up
goserelin acetate
worsening pleuritis carcinomatosa
goserelin acetate
severe dyspnea
goserelin acetate